|
- Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments
- Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session
SEOUL, South Korea, Dec. 5, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 5th that it participated in the 111th Radiological Society of North America (RSNA 2025) and presented real-world clinical use cases of its key brain imaging analysis AI solutions.
At the conference, Neurophet showcased its software 'Neurophet AQUA AD,' which supports monitoring of Alzheimer's disease treatment prescription, therapeutic response, and potential adverse effects. Neurophet AQUA AD provides precise brain imaging analysis throughout the administration of anti-amyloid antibody therapies by quantitatively analyzing magnetic resonance imaging (MRI) and positron emission tomography (PET) scans.
In addition, real-world clinical use cases of Neurophet AQUA AD were demonstrated during the AI Theater session held in the exhibition hall. In this session, Professor Chong Hyun Suh from the Department of Radiology at Asan Medical Center, University of Ulsan College of Medicine, delivered a lecture titled "AI-Powered Monitoring of Amyloid-Related Imaging Abnormalities in Anti-Amyloid Therapy: Neurophet AQUA AD."
Professor Suh introduced AI-based ARIA detection and quantification technologies that address the limitations of conventional manual approaches. He also elaborated how AI enhances the safety and clinical effectiveness of anti-amyloid therapies by presenting various real-world clinical cases in which patients receiving Alzheimer's disease treatments developed ARIA.
Through booth exhibition, Neurophet also presented Neurophet AQUA AD alongside its other solutions, including Neurophet AQUA, a brain neurodegeneration imaging analysis software, and Neurophet SCALE PET, a PET imaging quantification software.
The company highlighted the technological excellence of Neurophet AQUA MS, which was first unveiled at last year's RSNA. Neurophet AQUA MS is a software module integrated into Neurophet AQUA that analyzes brain images of patients with multiple sclerosis, a refractory central nervous system disorder. The solution received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October of last year.
Jake Junkil Been, Co-CEO of Neurophet, stated, "Neurophet AQUA AD has been gaining significant attention from major domestic and global companies in the field of imaging analysis for Alzheimer's disease treatment planning. Through partnerships with global medical device companies at RSNA 2025, we plan to accelerate the expansion of our key products in the North American market."
Meanwhile, RSNA 2025 is the world's largest radiology conference, attended by radiologists and global medical device industry professionals, and is held annually in Chicago, USA. This year's conference took place from November 30 to December 4 (local time).
About Neurophet
Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
- Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments
- Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session
SEOUL, South Korea, Dec. 5, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 5th that it participated in the 111th Radiological Society of North America (RSNA 2025) and presented real-world clinical use cases of its key brain imaging analysis AI solutions.
At the conference, Neurophet showcased its software 'Neurophet AQUA AD,' which supports monitoring of Alzheimer's disease treatment prescription, therapeutic response, and potential adverse effects. Neurophet AQUA AD provides precise brain imaging analysis throughout the administration of anti-amyloid antibody therapies by quantitatively analyzing magnetic resonance imaging (MRI) and positron emission tomography (PET) scans.
In addition, real-world clinical use cases of Neurophet AQUA AD were demonstrated during the AI Theater session held in the exhibition hall. In this session, Professor Chong Hyun Suh from the Department of Radiology at Asan Medical Center, University of Ulsan College of Medicine, delivered a lecture titled "AI-Powered Monitoring of Amyloid-Related Imaging Abnormalities in Anti-Amyloid Therapy: Neurophet AQUA AD."
Professor Suh introduced AI-based ARIA detection and quantification technologies that address the limitations of conventional manual approaches. He also elaborated how AI enhances the safety and clinical effectiveness of anti-amyloid therapies by presenting various real-world clinical cases in which patients receiving Alzheimer's disease treatments developed ARIA.
Through booth exhibition, Neurophet also presented Neurophet AQUA AD alongside its other solutions, including Neurophet AQUA, a brain neurodegeneration imaging analysis software, and Neurophet SCALE PET, a PET imaging quantification software.
The company highlighted the technological excellence of Neurophet AQUA MS, which was first unveiled at last year's RSNA. Neurophet AQUA MS is a software module integrated into Neurophet AQUA that analyzes brain images of patients with multiple sclerosis, a refractory central nervous system disorder. The solution received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October of last year.
Jake Junkil Been, Co-CEO of Neurophet, stated, "Neurophet AQUA AD has been gaining significant attention from major domestic and global companies in the field of imaging analysis for Alzheimer's disease treatment planning. Through partnerships with global medical device companies at RSNA 2025, we plan to accelerate the expansion of our key products in the North American market."
Meanwhile, RSNA 2025 is the world's largest radiology conference, attended by radiologists and global medical device industry professionals, and is held annually in Chicago, USA. This year's conference took place from November 30 to December 4 (local time).
About Neurophet
Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'
SEOUL, South Korea, Dec. 5, 2025 /PRNewswire/ -- Supercent, a fast-rising force in the mobile gaming industry, has made history by becoming the first South Korean company to enter the global Top 10 mobile game publishers by downloads, according to leading app analytics platform Sensor Tower.
In its latest annual rankings, Sensor Tower listed Supercent at No. 7 worldwide, marking the highest placement ever achieved by a South Korean game publisher since the rankings began in 2014. This milestone follows the company's initial entry into the global Top 10 at No. 10 last year — a remarkable three-spot climb in just 12 months, underscoring its rapid global ascent.
Breakout Hits Power Global Growth
Supercent's rise has been propelled by two major hits: "Pizza Ready" and "Snake Clash".
"Pizza Ready" dominated the hybrid casual space in 2025, ranking as the most-downloaded hybrid casual game globally. The title amassed 150 million downloads this year alone, contributing to nearly 40% of its 400 million lifetime installs. Impressively, it also ranked No. 3 among all global app launches since January 2023, and No. 1 among games, according to Sensor Tower.
The game's innovative ad strategy has been a key differentiator. Unlike typical mobile games that show ads within the first minute, "Pizza Ready" delays ad exposure until around three minutes into gameplay, allowing users to immerse themselves before encountering monetization. This user-centric approach has been praised for balancing engagement and revenue effectively.
Meanwhile, "Snake Clash" has emerged as a global hyper-casual phenomenon, surpassing 180 million lifetime downloads and ranking No. 4 in global hyper-casual downloads this year. Half of its downloads came in 2025 alone, highlighting its explosive growth. Departing from the genre's traditional reliance on ad monetization, "Snake Clash" implemented a more refined in-app purchase model with skins and packages — a move that significantly improved monetization and user satisfaction. In fact, 33% of user reviews praised the game's minimal ad experience, contributing to high player retention.
Breaking the Mold: A Milestone for South Korean Gaming
This entry into the Top 10 carries particular significance as it shatters the long-standing perception of South Korea as a "challenging market" for casual games. Despite possessing world-class development infrastructure and creative talent, the South Korean gaming industry has historically been heavily skewed toward domestic-focused MMORPGs, yielding few global successes in the casual genre for over a decade.
Industry observers view Supercent's rise as a watershed moment. By leveraging South Korea's robust infrastructure to break through global barriers, the company has effectively proved that the nation's development and creative capabilities can dominate the mass-market casual sector just as effectively as they have the hardcore genre.
AI-Powered Publishing: A Competitive Edge
Supercent is also gaining attention for its unique integration of AI technology and content strategy into its development and publishing pipeline — a rare achievement in South Korea. The company's AI-driven publishing system, data-informed decision-making, and content-first mindset have created a sustainable growth engine that sets it apart in a crowded market.
"Amid a flood of new mobile titles launching daily, Supercent continues to generate consistent, large-scale download momentum — not just fleeting viral hits," said Junsik Kong, CEO of Supercent. "This achievement is proof of our long-term growth potential and resilience in a fast-changing market."
Kong added, "By combining AI-powered systems, data analytics, and competitive content development, we're building a virtuous cycle of sustainable growth. Moving forward, we'll continue maximizing the synergy between AI and creativity to deliver successive global hits."
About Supercent
Founded in 2021, Supercent has surpassed 1.3 billion total downloads globally and boasts over 20 titles with more than 10 million downloads each. In August, the company expanded its headquarters to the Lotte World Tower in Jamsil, Seoul, and has been accelerating hiring and organizational growth in line with its global ambitions.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Supercent Breaks into the Global Top 10 Mobile Game Publishers at 7th - A First for South Korea
